Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · September 16, 2024

Efficacy of Semaglutide in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Lancet 2024 Sep 07;404(10456)949-961, MN Kosiborod, J Deanfield, R Pratley, BA Borlaug, J Butler, MJ Davies, SS Emerson, SE Kahn, DW Kitzman, I Lingvay, KW Mahaffey, MC Petrie, J Plutzky, S Rasmussen, C Rönnbäck, SJ Shah, S Verma, PE Weeke, AM Lincoff

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading